EAM Investors’s Spyre Therapeutics SYRE Stock Holding History

EAM Investors’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.36M	Buy	+60,393	New	+$4.41M	0.48%	92
2024 Q3	–	Sell	-17,938	Closed	-$422K	–	327
2024 Q2	$422K	Hold	17,938	–	–	0.07%	238
2024 Q1	$680K	Buy	+17,938	New	+$520K	0.11%	215
2018 Q3	–	Sell	-2,269	Closed	-$600K	–	366
2018 Q2	$600K	Hold	2,269	–	–	0.09%	273
2018 Q1	$563K	Buy	+2,269	New	+$410K	0.09%	265

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

EAM Investors's SYRE Position: Q2 2026 in Review

EAM Investors opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 60,393 shares worth $5.36M. The stake represents 0.48% of the portfolio and ranks #92 among its holdings. This is a return to the name: EAM Investors previously reported a position in SYRE as recently as Q2 2024.

EAM Investors first reported a position in SYRE in Q1 2018 and has held it in 5 quarters since. 267 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

EAM Investors held 60,393 shares of Spyre Therapeutics worth $5.36M as of Q2 2026.
Spyre Therapeutics was a new EAM Investors position in Q2 2026.
Spyre Therapeutics made up 0.48% of EAM Investors's portfolio in Q2 2026, its #92 holding.
EAM Investors first reported a position in Spyre Therapeutics in Q1 2018 and has held it in 5 quarters since.
267 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.